Difference between revisions of "Daunorubicin liposomal (DaunoXome)"
m |
|||
Line 14: | Line 14: | ||
*[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | ||
+ | |||
+ | ==History of changes in FDA indication== | ||
+ | * 4/8/1996: Initial FDA approval | ||
==References== | ==References== | ||
Line 23: | Line 26: | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
+ | |||
+ | [[Category:Sarcoma medications]] | ||
+ | |||
+ | [[Category:Drugs FDA approved in 1996]] |
Revision as of 17:12, 3 November 2014
Also known as daunorubicin citrate liposome injection.
General information
Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)[4]
- Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/8/1996: Initial FDA approval
References
- ↑ 1.0 1.1 Daunorubicin liposomal (DaunoXome) package insert
- ↑ Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)
- ↑ DaunoXome manufacturer's website
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)